Sirolimus in Treatment of Proteinuric Flares of Lupus Nephritis
Status:
Not yet recruiting
Trial end date:
2023-10-30
Target enrollment:
Participant gender:
Summary
This a single-centre, one-arm, open-label pilot study. Eligible patients with mild
proteinuric flares of lupus nephritis Class III/IV±V are received sirolimus without changing
previous immunosuppressive medication during 12-week follow-up.
Primary Objective:
- To investigate the efficacy of sirolimus for mild proteinuric flares in patients with
Class III/IV±V lupus nephritis
Secondary Objective:
- To assess the safety and tolerability of sirolimus treatment for mild proteinuric flares
in patients with Class III/IV±V lupus nephritis